JAGX

Jaguar Health Inc.

Price

$7.70

return (12m)

-99.32%

p/e

-0.11

p/bv

1.21

DIVIDEND YIELD

0.00%

JAGX price

Jaguar Health

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment JAGX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-33.33%

3 months

-82.66%

1 year

-99.32%

2 years

-99.95%

5 years

-100.00%

10 years

-100.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals JAGX

Valuation

P/E

-0.11

Sector -3.51

Industry -3.51

P/BV

1.21

Sector 1.99

Industry 1.99

P/Revenue (PSR)

0.21

Sector 2.05

Industry 2.05

EV/EBITDA

-0.55

Sector -215.71

Industry -215.71

EV/EBIT

-0.51

Sector -46.22

Industry -46.22

P/EBITDA

-0.18

Sector -21.18

Industry -21.18

P/EBIT

-0.17

Sector -28.19

Industry -28.19

P/Total Assets

0.17

Sector 1.18

Industry 1.18

P/Net Current Assets

-0.51

Sector -10.00

Industry -10.00

P/Working Capital

-0.76

Sector 1.60

Industry 1.60

EPS

-64.79

Sector -1.80

Industry -1.80

BVPS

6.08

Sector 2.03

Industry 2.03

Efficiency

Gross Margin

82.31%

Sector 41.43%

Industry 41.43%

EBITDA Margin

-575.92%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

-620.16%

Sector -4,221,130.86%

Industry -4,221,130.86%

Operating Margin

-93.10%

Sector -35.37%

Industry -35.37%

Net Profit Margins

-100.00%

Sector -36.08%

Industry -36.08%

Asset Turnover

0.04

Sector 0.03

Industry 0.03

Profitability

ROE

-1,065.23%

Sector -57.16%

Industry -57.16%

ROA

-153.30%

Sector -59.52%

Industry -59.52%

ROIC

-74.35%

Sector -2,363.38%

Industry -2,363.38%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

0.69

Sector 2.91

Industry 2.91

Net Debt / EBITDA

0.29

Sector -14,058,646.59

Industry -14,058,646.59

Net Debt / EBIT

0.27

Sector -8.05

Industry -8.05

Net Debt / Equity

-0.42

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.35

Sector 0.00

Industry 0.00

Equity/Assets

0.14

Sector 0.46

Industry 0.46

Liabilities/Assets

0.86

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

45.03%

Sector -

Industry -

5Y Earnings CAGR

-0.07%

Sector -

Industry -

Fundamentals JAGX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
JAGX Jaguar Health Inc.	$7.70	-99.32%	0.00%	-0.11	1.21	-1,065.23%	-100.00%
JNJ Johnson & Johnson	$271.22	54.34%	1.96%	30.90	7.65	24.76%	21.48%
PFE Pfizer Inc.	$28.67	29.16%	6.08%	37.23	1.89	5.07%	6.80%
ABBV AbbVie Inc.	$264.40	23.67%	2.60%	73.78	-78.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.80	-26.75%	4.80%	9.44	5.02	53.11%	35.32%
MRK Merck & Co. Inc.	$148.78	96.81%	2.29%	114.37	8.64	7.56%	4.77%
AZN AstraZeneca PLC	$166.58	14.87%	1.95%	19.85	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.86	50.75%	4.09%	13.50	5.62	41.59%	18.87%
ZTS Zoetis Inc.	$71.05	-49.54%	2.99%	11.07	9.27	83.77%	27.69%
AMGN Amgen Inc.	$414.61	56.07%	2.43%	25.29	18.92	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$788.04	40.30%	0.47%	18.75	2.56	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$113.90	54.44%	0.00%	32.57	93.84	288.13%	24.86%
MCK McKesson Corporation	$866.64	14.53%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$526.19	36.41%	0.00%	30.03	6.53	21.76%	35.00%
CAH Cardinal Health Inc.	$220.22	45.11%	0.93%	30.18	-18.99	-62.92%	0.67%
ARGX argenx SE	$959.49	34.83%	0.00%	1.85	2.21	119.72%	44.81%
HRMY Harmony Biosciences Holdings Inc.	$41.26	49.98%	0.00%	13.11	2.38	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

JAGX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Jaguar Health

Jaguar Health Inc.

Average Investor10 user rating

4.0 (0 people)

United States

13 years

Founded: 2013

2015

Time since IPO - 11 years

34

Employees

Jaguar Health, Inc. is a U.S.-based biotechnology company focused on developing plant-based medicines for gastrointestinal disorders in humans and animals. The company specializes in therapies derived from botanical sources, targeting conditions related to intestinal health.

Its business model centers on the development, regulatory approval, and commercialization of treatments for chronic and infectious gastrointestinal diseases.

Core activities include:

Development of plant-based gastrointestinal therapies
Clinical research for chronic and infectious enteric diseases
Commercialization of approved treatments
Expansion of therapeutic applications and formulations
Partnerships for international distribution and regulatory access

The company’s portfolio includes treatments targeting diarrhea associated with various medical conditions, as well as therapies for chronic gastrointestinal disorders and neglected tropical diseases.

Jaguar Health operates primarily in the United States, with expansion efforts in Latin America, Africa, and other emerging markets, often through partnerships and regulatory initiatives.

Its performance is influenced by clinical trial outcomes, regulatory approvals, funding availability, competition in the biotechnology sector, and demand for gastrointestinal treatments.

Jaguar Health, Inc. is listed on the Nasdaq under the ticker JAGX.

History and Development

Jaguar Health traces its origins to 2013, with the founding of Jaguar Animal Health, focused on developing plant-derived therapies for gastrointestinal conditions.

A key milestone occurred in 2017, when Jaguar Animal Health merged with Napo Pharmaceuticals, combining botanical research capabilities with clinical development and commercialization expertise.

Following the merger, the company focused on advancing its lead products, securing regulatory approvals, and expanding clinical research into additional indications.

Over time, Jaguar Health broadened its international strategy, pursuing regulatory approvals and partnerships in regions affected by gastrointestinal diseases, including emerging markets.

Today, the company continues to develop plant-based therapeutics, focusing on specialized gastrointestinal conditions and expanding its presence in global healthcare markets.

Additional Information

Jaguar Health Inc. (United States) is listed on the Nasdaq and has a market capitalization of $5.95 million, with shareholders equity totaling $4.92 million.

The company employs approximately 34 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Jaguar Health Inc. reported $27.82 million in revenue, generating net income of $-52.42 million.

Key financial metrics include a P/E ratio of -0.11, a price-to-book (P/B) ratio of 1.21, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker JAGX.

Market cap

$5.95 million

Net worth

$4.92 million

$4,921,000.00

Assets

$34.19 million

$34,194,000.00

Total Shares Outstanding

809.12 Thousand

809,000

Average Daily Trading Volume

$1.47 million

$1,467,262.86

Sector

Health Care

Industry

Biotechnology

JAGX

JAGX revenue and profits

Financial Results JAGX

DRAG THE FRAME TO SEE MORE DATA

JAGX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$866.64 14,53% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$220.22 45,11% (12M)

P/E

30.18

0.93%

ROE

-62.92%

P/BV

-18.99

JNJ - Johnson & Johnson

$271.22 54,34% (12M)

P/E

30.90

1.96%

ROE

24.76%

P/BV

7.65

ABBV - AbbVie

$264.40 23,67% (12M)

P/E

73.78

2.60%

ROE

-106.44%

P/BV

-78.53

MRK - Merck & Co.

$148.78 96,81% (12M)

P/E

114.37

2.29%

ROE

7.56%

P/BV

8.64

AZN - AstraZeneca

$166.58 14,30% (12M)

P/E

19.85

1.95%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$28.67 29,16% (12M)

P/E

37.23

6.08%

ROE

5.07%

P/BV

1.89

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$866.64 14,53% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$220.22 45,11% (12 M)

P/L

30.18

0.93%

ROE

-62.92%

P/VP

-18.99

JNJ - Johnson & Johnson

$271.22 54,34% (12 M)

P/L

30.90

1.96%

ROE

24.76%

P/VP

7.65

ABBV - AbbVie

$264.40 23,67% (12 M)

P/L

73.78

2.60%

ROE

-106.44%

P/VP

-78.53

MRK - Merck & Co.

$148.78 96,81% (12 M)

P/L

114.37

2.29%

ROE

7.56%

P/VP

8.64

AZN - AstraZeneca

$166.58 14,30% (12 M)

P/L

19.85

1.95%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$28.67 29,16% (12 M)

P/L

37.23

6.08%

ROE

5.07%

P/VP

1.89

Frequently Asked Questions

What is the price of Jaguar Health (JAGX) today?

The current price of Jaguar Health (JAGX) is $7.70. The stock began the year trading around $0.93 and is currently priced at $7.70. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Jaguar Health (JAGX) pay dividends?

Jaguar Health (JAGX) did not pay dividends over the past year.

Is Jaguar Health (JAGX) a good investment?

Jaguar Health (JAGX) is currently trading at $7.70 with a P/E ratio of -0.11. This represents a -292% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -99.32%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Jaguar Health (JAGX) stock?

You can buy Jaguar Health (JAGX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol JAGX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Jaguar Health (JAGX) yield today?

Over the past month, Jaguar Health (JAGX) has returned -33.33% — -99.32% over the past year, and -100.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Jaguar Health (JAGX) today at the current price of $7.70 your total investment would be $770.00.

Based on historical performance, the investment would have grown to approximately:

$5.24 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

JAGX

Jaguar Health Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment JAGX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING JAGX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Jaguar Health

Jaguar Health Inc.

United States

13 years

2015

34

History and Development

Additional Information

PROFIT X PRICE JAGX

Financial Results JAGX

JAGX cash flow

Asset, Revenue and Profit Growth - JAGX

JAGX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions